Data Sheet 2: BCL-XL in Myeloproliferative Neoplasm Progression

A 10.8 MB PDF research article by Chunyan Wu, last updated in June 2026, analyzes bone marrow mesenchymal stromal cells from patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The study investigates the role of BCL-XL in apoptosis resistance and fibrotic progression, evaluating the effects of inhibitors ABT-263 and ruxolitinib.

Use Cases

• Analyzing the expression of BCL-XL and other BCL-2 family members in malignant hematopoietic and stromal cells based on the described immunofluorescence and western blotting results.
• Modeling the synergistic effects of combined BCL-XL and JAK2 inhibition on apoptosis and fibrosis based on the described pharmacologic experiments.
• Investigating the cooperative engagement of TGF-β/SMAD3 and JAK2/STAT3 signaling pathways in stromal fibrotic activation based on the described mechanistic findings.

Strengths

• The dataset is a detailed research article with a specific focus on BCL-XL's role in MPN progression, providing mechanistic insights.
• It includes experimental results from multiple techniques such as flow cytometry, western blotting, and transmission electron microscopy.
• The data is openly shared under a CC-BY-4.0 license, facilitating reuse.

Limitations

• The primary data format is a PDF, which may require extraction and structuring for computational analysis.
• Row and column counts for underlying experimental data are unknown, limiting suitability assessment.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Analysis of patient-derived bone marrow mesenchymal stromal cells using cell counting, immunofluorescence, flow cytometry, western blotting, and microscopy.

Freshness

Last updated 2026-06-02 05:40:27; freshness should be verified.